{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:13:24Z","timestamp":1782159204285,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jval.2012.08.2201","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T13:08:48Z","timestamp":1355490528000},"page":"1059-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Comparison of Generic, Condition-Specific, and Mapped Health State Utility Values for Multiple Myeloma Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Donna","family":"Rowen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Brazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Gaugris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.08.2201_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2012.08.2201_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","article-title":"Multiattribute and single-attribute utility functions for the health utilities index mark 3 system","volume":"40","author":"Feeny","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2012.08.2201_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"10.1016\/j.jval.2012.08.2201_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2012.08.2201_bib5","series-title":"Measuring and Valuing Health for Economic Evaluation","author":"Brazier","year":"2007"},{"key":"10.1016\/j.jval.2012.08.2201_bib6","unstructured":"National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute of Health and Clinical Excellence, 2008."},{"key":"10.1016\/j.jval.2012.08.2201_bib7","series-title":"Assessment and Appraisal of Oncology Medicines: Does NICE's Approach Include All Relevant Elements? What Can Be Learnt from International HTA Experiences?","author":"Garau","year":"2009"},{"key":"10.1016\/j.jval.2012.08.2201_bib8","series-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.jval.2012.08.2201_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X10379646","article-title":"Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire","volume":"31","author":"Yang","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.08.2201_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0272989X10364846","article-title":"The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D","volume":"31","author":"Young","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.08.2201_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11136-008-9428-0","article-title":"The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis","volume":"18","author":"Young","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2012.08.2201_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jval.2011.01.004","article-title":"Deriving a preference-based measure for cancer using the EORTC QLQ-C30","volume":"14","author":"Rowen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.08.2201_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2012.08.2201_bib14","unstructured":"Longworth L., Rowen D. NICE DSU Technical Support Document 10: the use of mapping methods to estimate health state utility values. www.nicedsu.org.uk. [Accessed September 1, 2011]."},{"key":"10.1016\/j.jval.2012.08.2201_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1524-4733.2008.00405.x","article-title":"Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data","volume":"12","author":"McKenzie","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.08.2201_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1477-7525-6-51","article-title":"Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?","volume":"6","author":"Barton","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2012.08.2201_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00019053-200927060-00005","article-title":"Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies","volume":"27","author":"Chuang","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2012.08.2201_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16320","article-title":"Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome)","volume":"16","author":"Brazier","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2012.08.2201_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.08.2201_bib20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1524-4733.2009.00569.x","article-title":"Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments","volume":"12","author":"Kontodimopoulos","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.08.2201_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-010-0233-7","article-title":"Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences","volume":"11","author":"Crott","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2012.08.2201_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00195.x","article-title":"Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients","volume":"10","author":"Wu","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.08.2201_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1524-4733.2009.00545.x","article-title":"A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire","volume":"12","author":"Pickard","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.08.2201_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-8-141","article-title":"Brazier J, Stolk EA. Mapping onto EQ-5D for patients in poor health","volume":"8","author":"Versteegh","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2012.08.2201_bib25","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/JTO.0b013e3181f77a6a","article-title":"Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer","volume":"5","author":"Jang","year":"2010","journal-title":"J Thor Oncol"},{"key":"10.1016\/j.jval.2012.08.2201_bib26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s11136-011-0037-y","article-title":"Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients","volume":"21","author":"Kim","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2012.08.2201_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0272989X11427761","article-title":"Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D","volume":"32","author":"Versteegh","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.08.2201_bib28","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.jval.2012.08.2201_bib29","series-title":"Evaluation of Chemotherapeutic Agents","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","author":"Karnofsky","year":"1949"},{"key":"10.1016\/j.jval.2012.08.2201_bib30","series-title":"Statistical Power Analysis for the Behavioural Sciences","author":"Cohen","year":"1977"},{"key":"10.1016\/j.jval.2012.08.2201_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","article-title":"A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures","volume":"11","author":"Brazier","year":"2010","journal-title":"Eur J Health Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512039216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512039216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:11:56Z","timestamp":1761095516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512039216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1098301512039216"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.08.2201","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Generic, Condition-Specific, and Mapped Health State Utility Values for Multiple Myeloma Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2012.08.2201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}